First AD

Second AD

MARIPOSA Study Insights 

Please comment on the rationale for the use of amivantamab and lazertinib in 1L EGFR-mutant NSCLC and discuss recently presented efficacy and safety data from MARIPOSA. Cho, et al. ESMO 2023. Abstract LBA14

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Lung Cancer

JAN-22-OSD1275 - /clinical/lung-cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates  

Peer Exchange

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial. 

Treatment Strategies for NSCLC with Non-Actionable Mutations 

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02 

Exploring the TROPION-Lung04 Study 

Exploring Dato-DXd Combinations as First-Line Therapy for Advanced NSCLC 

Navigating Between ADCs in NSCLC

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2 

Osimertinib Monotherapy vs. Combination Therapy: Patient Selection in EGFR-Mutant Advanced NSCLC 

Optimizing Therapy Selection in EGFR Mutant NSCLC 

ASCO 2024 Updates: Novel Approaches in NSCLC Therapy 

Overview of TROP2 & Potential Role of TROP2-Directed ADCs in NSCLC  

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape 

Targeting of HER3: Insights from HERTHENA-Lung01 

Challenges and Learnings from EVOKE-01 

Key ADC Studies at ASCO 2024 

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd 

Patient Selection and Sequencing of NSCLC ADCs 